# Mohamad Mohty

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mohamad-mohty/

## Facts

| Field | Value |
| --- | --- |
| Citations | 63,879 |
| Field | Hematopoietic Stem Cell Transplantation |
| h-index | 127 |
| i10-index | 868 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5020996390 |
| ORCID iD | https://orcid.org/0000-0002-7264-808X |
| Works | 2,107 |

## Researcher papers

- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results](https://scholariq.org/papers/elranatamab-in-relapsed-or-refractory-multiple-myeloma-phase-2-magnetismm-3/)
- [Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation](https://scholariq.org/papers/diagnosis-and-severity-criteria-for-sinusoidal-obstruction-syndrome-veno/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial](https://scholariq.org/papers/a-simplified-frailty-scale-predicts-outcomes-in-transplant-ineligible-patients/)
- [Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy](https://scholariq.org/papers/standardizing-definitions-of-hematopoietic-recovery-graft-rejection-graft/)
- [Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial](https://scholariq.org/papers/maintenance-with-daratumumab-or-observation-following-treatment-with-bortezomib/)
- [Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee](https://scholariq.org/papers/personalizing-busulfan-based-conditioning-considerations-from-the-american/)

## Researcher topics

- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.